Researchers at Mass General Brigham have started an effort to develop brain-computer interfaces (BCI) for people with neurological diseases or brain injuries, including amyotrophic lateral sclerosis (ALS). BCI technologies rely on a person’s unique brain signaling patterns to interpret their intentions, then use that information to control a device…
Researchers at the University of Waterloo will use a CA$125,000 (about $93,000) grant from the ALS Society of Canada and Brain Canada to better understand how proteins become misplaced in cells and build into the toxic clumps that mark amyotrophic lateral sclerosis (ALS). Led by Dale Martin, PhD,…
Taking part in certain recreational activities, including gardening, golfing, woodworking, and hunting, may increase the risk of developing amyotrophic lateral sclerosis (ALS), especially for men, according to a new study. While the causes of ALS still are not well understood, several risk factors have been identified. There’s evidence…
A disorder such as amyotrophic lateral sclerosis (ALS) can be confusing and traumatic for children, particularly if the person with the disease is a family member or close friend. A new animated short film, “LUKi & The Lights,” seeks to help young people understand and cope with the complexities…
Some 20 U.S. organizations with a focus on amyotrophic lateral sclerosis (ALS) have put their names on a letter that seeks to help shape Congressional funding priorities for the federal legislative fiscal year 2025 to better serve the ALS community. The correspondence from the nonprofits, sent last week, was…
Coave Therapeutics has received a grant from the ALS Association to support the development of its gene therapy candidate CTx-TFEB for amyotrophic lateral sclerosis (ALS). The grant, made through the Lawrence and Isabel Barnett Drug Development Program, is part of the $2.9 million the ALS Association…
Daily treatment with monepantel — a drug widely used in veterinary medicine — was shown to reduce the rate of disease progression by as much as 58% in people with amyotrophic lateral sclerosis (ALS) or motor neuron disease (MND), according to top-line data from a Phase 1 trial.
Blocking a protein called PTP sigma led to better nerve survival and motor function in a mouse model of amyotrophic lateral sclerosis (ALS) caused by mutations in the C9ORF72 gene — leading the researchers to highlight this strategy for potentially treating this genetic ALS form. Data from cell models…
Relyvrio (sodium phenylbutyrate and taurursodiol), an approved treatment for people with amyotrophic lateral sclerosis (ALS), has failed to meet its primary goal of slowing disease progression in an ongoing Phase 3 clinical trial designed to confirm its effectiveness. That’s according to new data from the trial, dubbed PHOENIX,…
New data show that blood-based measures, including levels of markers of nerve damage and chemical DNA modifications, can help predict which individuals with amyotrophic lateral sclerosis (ALS) will have faster disease progression over time. However, because the disease course may be altered with Radicava or Radicava ORS —…
